compounded semaglutide new market Troubling Findings in Study of GLP-1 Compounders Best Semaglutide Options for 2026:

doi:10.1016/j.atherosclerosis.2017.01.009 Gajendragadkar PR, Hubsch A, Maki-Petaja KM, Serg M, Wilkinson IB, Cheriyan J

The Problems with Current GLP-1 Guidelines Traditional medicine waits to prescribe GLP-1 medications until a patients BMI hits 30 (obesity) or 27 with at least one weight-related health condition, such as high blood pressure or high cholesterol

References 1.Hesketh S.J., Stansfield B.N., Stead A.C., Burniston J.G

However, studies show approximately 75-80% of weight lost comes from fat mass when protein intake and resistance training are maintained

Educational background: Semaglutide as a molecule was originally developed for type 2 diabetes by Novo Nordisk and is sold under the brand names Ozempic (for diabetes) and Wegovy (for chronic weight management, introduced for weight management in 2021)

But not with shortcuts